Tiziana Life Sciences Ltd
NASDAQ:TLSA · NASDAQ Global Market
+$0.03 today
Vol 0.29M · Avg 0.21M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $4.0M |
| Receivables | $4.3M |
| Other Current | $285.0K |
| Total Current Assets | $8.6M |
| PP&E (Net) | $499.0K |
| Long-term Investments | $2.4M |
| Total Non-current Assets | $2.9M |
| Total Assets | $11.5M |
Analysis
Selected assets total $11.5M for Latest. The largest visible component is Receivables at $4.3M, about 37.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.0M +7.7% | $3.7M +214.8% | $1.2M -93.5% | $18.1M -57.0% | $42.2M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $4.3M +15.3% | $3.7M -39.0% | $6.1M +3.3% | $5.9M +11.2% | $5.3M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $8.6M +13.9% | $7.5M +2.3% | $7.3M -69.8% | $24.3M -50.1% | $48.7M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $499.0K +166.8% | $187.0K -36.2% | $293.0K -24.7% | $389.0K +2188.2% | $17.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 -100.0% | $130.0K | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $2.4M -31.9% | $3.6M -21.2% | $4.6M +152.2% | $1.8M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $0 | $0 | $0 | $0 | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $2.9M -22.1% | $3.8M -22.1% | $4.8M +120.8% | $2.2M +1393.2% | $147.0K | -$15.3B | $14.8B | $11.3B |
| Total Assets | $11.5M +1.9% | $11.3M -7.4% | $12.2M -54.0% | $26.5M -45.8% | $48.8M | $13.3B | $11.9B | $10.6B |
| Account Payables | $7.2M +28.5% | $5.6M +34.9% | $4.1M -16.6% | $5.0M +12.6% | $4.4M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 -100.0% | $1.4M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $530.0K | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | -$3.0K -125.0% | $12.0K -14.3% | $14.0K +55.6% | $9.0K +100.7% | -$1.3M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $11.2M +52.5% | $7.3M +12.4% | $6.5M -1.9% | $6.7M -11.7% | $7.5M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $234.0K | $0 -100.0% | $109.0K -55.1% | $243.0K | $0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $11.4M +55.7% | $7.3M +10.5% | $6.6M -3.7% | $6.9M -8.5% | $7.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $121.0K +9.0% | $111.0K +7.8% | $103.0K +1.0% | $102.0K +0.0% | $102.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$44.4M +69.3% | -$144.8M -8.3% | -$133.7M -15.0% | -$116.3M -7.6% | -$108.1M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $9.7M -91.7% | $117.0M -0.1% | $117.1M +1.3% | $115.6M -3.0% | $119.2M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 -100.0% | $8.6M +20.1% | $7.1M +21.1% | $5.9M -59.4% | $14.5M | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $52.0K -98.7% | $3.9M -28.9% | $5.5M -71.7% | $19.6M -52.6% | $41.3M | $9.1B | $7.7B | $3.3B |
| Total Debt | $456.0K +330.2% | $106.0K -57.1% | $247.0K -32.3% | $365.0K -73.1% | $1.4M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$3.6M +1.8% | -$3.6M -286.5% | -$936.0K +94.7% | -$17.8M +56.5% | -$40.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$509.75M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$264.46M
MacroGenics, Inc.
NASDAQ:MGNX
$260.93M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$214.13M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.04M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$71.21M
eXoZymes, Inc.
NASDAQ:EXOZ
$62.62M
OKYO Pharma Limited
NASDAQ:OKYO
$60.62M
Estrella Immunopharma, Inc.
ESLA
$43.68M
Anebulo Pharmaceuticals, Inc.
ANEB
$15.92M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does TLSA have?
Tiziana Life Sciences Ltd (TLSA) reported $4.01M in cash and equivalents in fiscal 2025.
How much debt does TLSA carry?
Tiziana Life Sciences Ltd (TLSA) reported $456,000.00 of total debt, with net debt of -$3,554,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.